The efficacy of tumor debulking surgery is improved by adjuvant immunotherapy using imiquimod and anti-CD40

BMC Cancer

Volumn 14, Issue 1, 2014, Pages

  Khong, Andrea ^a,b   Cleaver, Amanda L ^a,b   Fahmi Alatas, Muhammad ^a,b   Wylie, Ben C ^a,b,d   Connor, Theresa ^a,b,d   Fisher, Scott A ^a,b   Broomfield, Steve ^b,c   Lesterhuis, Willem J ^a,b   Currie, Andrew J ^b,c   Lake, Richard A ^a,b   Robinson, Bruce W ^a,b  

^a UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^b National Centre for Asbestos Related Diseases   (Australia)

^c MURDOCH UNIVERSITY   (Australia)

^d UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

Author keywords

Anti CD40; Debulk; Imiquimod; Immunotherapy; Mesothelioma; Surgery; Tumor

Indexed keywords

BUPRENORPHINE; FGK 45; IMIQUIMOD; MONOCLONAL ANTIBODY; UNCLASSIFIED DRUG; AMINOQUINOLINE DERIVATIVE; CD40 ANTIGEN; IMMUNOLOGICAL ADJUVANT; MEMBRANE PROTEIN; TLR7 PROTEIN, MOUSE; TOLL LIKE RECEPTOR 7;

ADJUVANT THERAPY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER ADJUVANT THERAPY; CANCER SURVIVAL; CD4 LYMPHOCYTE COUNT; CD8+ T LYMPHOCYTE; CELL KILLING; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; CYTOREDUCTIVE SURGERY; DRUG EFFICACY; FEMALE; IMMUNE RESPONSE; MALIGNANT MESOTHELIOMA; MOUSE; NONHUMAN; POLYGLACTIN SUTURE; STAPLER; T LYMPHOCYTE ACTIVATION; TREATMENT RESPONSE; TUMOR GROWTH; TUMOR REGRESSION; AGONISTS; ANIMAL; ANTAGONISTS AND INHIBITORS; BAGG ALBINO MOUSE; DRUG ADMINISTRATION; EXPERIMENTAL NEOPLASM; IMMUNOTHERAPY; MESOTHELIOMA; METABOLISM; PATHOLOGY; PROCEDURES; TREATMENT OUTCOME; TUMOR CELL LINE;

ADJUVANTS, IMMUNOLOGIC; AMINOQUINOLINES; ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGENS, CD40; CD8-POSITIVE T-LYMPHOCYTES; CELL LINE, TUMOR; CYTOREDUCTION SURGICAL PROCEDURES; DRUG ADMINISTRATION SCHEDULE; FEMALE; IMMUNOTHERAPY; MEMBRANE GLYCOPROTEINS; MESOTHELIOMA; MICE; MICE, INBRED BALB C; NEOPLASMS, EXPERIMENTAL; TOLL-LIKE RECEPTOR 7; TREATMENT OUTCOME;

EID: 84924369766     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-14-969     Document Type: Article

References (30)

1. Carrato A: Adjuvant treatment of colorectal cancer. Gastrointest Cancer Res 2008,2(4 Suppl):S42-S46.
2. Cole BF, Gelber RD, Gelber S, Coates AS, Goldhirsch A: Polychemotherapy for early breast cancer: an overview of the randomised clinical trials with quality-adjusted survival analysis. Lancet 2001,358(9278):277-286. 10.1016/S0140-6736(01)05483-6
3. Yan TD, Cao CQ, Boyer M, Tin MM, Kennedy C, McLean J, Bannon PG, McCaughan BC: Improving survival results after surgical management of malignant pleural mesothelioma: an Australian institution experience. Ann Thorac Cardiovasc Surg 2011,17(3):243-249. 10.5761/atcs.oa.10.01572
4. Nowak AK: Immunological checkpoint inhibitors enter adolescence. Lancet Oncol 2013,14(11):1035-1037. 10.1016/S1470-2045(13)70401-7
5. Vacchelli E, Galluzzi L, Eggermont A, Fridman WH, Galon J, Sautes-Fridman C, Tartour E, Zitvogel L, Kroemer G: Trial watch: FDA-approved Toll-like receptor agonists for cancer therapy. Oncoimmunology 2012,1(6):894-907. 10.4161/onci.20931
6. Kurts C, Robinson BW, Knolle PA: Cross-priming in health and disease. Nat Rev Immunol 2010,10(6):403-414. 10.1038/nri2780
7. Beatty GL, Chiorean EG, Fishman MP, Saboury B, Teitelbaum UR, Sun W, Huhn RD, Song W, Li D, Sharp LL, Torigian DA, O'Dwyer PJ, Vonderheide RH: CD40 agonists alter tumor stroma and show efficacy against pancreatic carcinoma in mice and humans. Science 2011,331(6024):1612-1616. 10.1126/science.1198443
8. Vonderheide RH, Burg JM, Mick R, Trosko JA, Li D, Shaik MN, Tolcher AW, Hamid O: Phase I study of the CD40 agonist antibody CP-870,893 combined with carboplatin and paclitaxel in patients with advanced solid tumors. Oncoimmunology 2013,2(1):e23033. 10.4161/onci.23033
9. Stumbles PA, Himbeck R, Frelinger JA, Collins EJ, Lake RA, Robinson BW: Cutting edge: tumor-specific CTL are constitutively cross-armed in draining lymph nodes and transiently disseminate to mediate tumor regression following systemic CD40 activation. J Immunol 2004,173(10):5923-5928. 10.4049/jimmunol.173.10.5923
10. Broomfield SA, van der Most RG, Prosser AC, Mahendran S, Tovey MG, Smyth MJ, Robinson BW, Currie AJ: Locally administered TLR7 agonists drive systemic antitumor immune responses that are enhanced by anti-CD40 immunotherapy. J Immunol 2009,182(9):5217-5224. 10.4049/jimmunol.0803826
11. Marzo AL, Lake RA, Robinson BW, Scott B: T-cell receptor transgenic analysis of tumor-specific CD8 and CD4 responses in the eradication of solid tumors. Cancer Res 1999,59(5):1071-1079.
12. Oehen S, Brduscha-Riem K: Differentiation of naive CTL to effector and memory CTL: correlation of effector function with phenotype and cell division. J Immunol 1998,161(10):5338-5346.
13. Lyons AB, Parish CR: Determination of lymphocyte division by flow cytometry. J Immunol Methods 1994,171(1):131-137. 10.1016/0022-1759(94)90236-4
14. Currie AJ, Van Der Most RG, Broomfield SA, Prosser AC, Tovey MG, Robinson BW: Targeting the effector site with IFN-alphabeta-inducing TLR ligands reactivates tumor-resident CD8 T cell responses to eradicate established solid tumors. J Immunol 2008,180(3):1535-1544. 10.4049/jimmunol.180.3.1535
15. Sinha P, Clements VK, Ostrand-Rosenberg S: Reduction of myeloid-derived suppressor cells and induction of M1 macrophages facilitate the rejection of established metastatic disease. J Immunol 2005,174(2):636-645. 10.4049/jimmunol.174.2.636
16. Kruklitis RJ, Singhal S, Delong P, Kapoor V, Sterman DH, Kaiser LR, Albelda SM: Immuno-gene therapy with interferon-beta before surgical debulking delays recurrence and improves survival in a murine model of malignant mesothelioma. J Thorac Cardiovasc Surg 2004,127(1):123-130. 10.1016/j.jtcvs.2003.08.034
17. Predina J, Eruslanov E, Judy B, Kapoor V, Cheng G, Wang LC, Sun J, Moon EK, Fridlender ZG, Albelda S, Singhal S: Changes in the local tumor microenvironment in recurrent cancers may explain the failure of vaccines after surgery. Proc Natl Acad Sci U S A 2013,110(5):E415-E424. 10.1073/pnas.1211850110
18. Marabelle A, Kohrt H, Sagiv-Barfi I, Ajami B, Axtell RC, Zhou G, Rajapaksa R, Green MR, Torchia J, Brody J, Luong R, Rosenblum MD, Steinman L, Levitsky HI, Tse V, Levy R: Depleting tumor-specific Tregs at a single site eradicates disseminated tumors. J Clin Invest 2013,123(6):2447-2463. 10.1172/JCI64859
19. Nelson DJ: Turning the tumor microenvironment into a self vaccine site. Oncoimmunology 2012,1(6):989-991. 10.4161/onci.20238
20. Jackaman C, Nelson DJ: Intratumoral interleukin-2/agonist CD40 antibody drives CD4+ - independent resolution of treated-tumors and CD4+ - dependent systemic and memory responses. Cancer Immunol Immunother 2012,61(4):549-560. 10.1007/s00262-011-1120-5
21. Jackaman C, Lew AM, Zhan Y, Allan JE, Koloska B, Graham PT, Robinson BW, Nelson DJ: Deliberately provoking local inflammation drives tumors to become their own protective vaccine site. Int Immunol 2008,20(11):1467-1479. 10.1093/intimm/dxn104
22. Broomfield S, Currie A, Van Der Most RG, Brown M, Van Bruggen I, Robinson BW, Lake RA: Partial, but not complete, tumor-debulking surgery promotes protective antitumor memory when combined with chemotherapy and adjuvant immunotherapy. Cancer Res 2005,65(17):7580-7584.
23. Khong A, Brown MD, Vivian JB, Robinson BW, Currie AJ: Agonistic anti-CD40 antibody therapy is effective against postoperative cancer recurrence and metastasis in a murine tumor model. J Immunother 2013,36(7):365-372. 10.1097/CJI.0b013e31829fb856
24. Warger T, Rechtsteiner G, Schmid B, Osterloh P, Schild H, Radsak MP: Transcutaneous immunization with imiquimod is amplified by CD40 ligation and results in sustained cytotoxic T-lymphocyte activation and tumor protection. Clin Rev Allergy Immunol 2007,32(1):57-66. 10.1007/BF02686082
25. Aranda F, Llopiz D, Diaz-Valdes N, Riezu-Boj JI, Bezunartea J, Ruiz M, Martinez M, Durantez M, Mansilla C, Prieto J, Lasarte JJ, Borrás-Cuesta F, Sarobe P: Adjuvant combination and antigen targeting as a strategy to induce polyfunctional and high-avidity T-cell responses against poorly immunogenic tumors. Cancer Res 2011,71(9):3214-3224. 10.1158/0008-5472.CAN-10-3259
26. Khong A, Nelson DJ, Nowak AK, Lake RA, Robinson BW: The use of agonistic anti-CD40 therapy in treatments for cancer. Int Rev Immunol 2012,31(4):246-266. 10.3109/08830185.2012.698338
27. Murphy WJ, Welniak L, Back T, Hixon J, Subleski J, Seki N, Wigginton JM, Wilson SE, Blazar BR, Malyguine AM, Sayers TJ, Wiltrout RH: Synergistic anti-tumor responses after administration of agonistic antibodies to CD40 and IL-2: coordination of dendritic and CD8+ cell responses. J Immunol 2003,170(5):2727-2733. 10.4049/jimmunol.170.5.2727
28. Lesterhuis WJ, Salmons J, Nowak AK, Rozali EN, Khong A, Dick IM, Harken JA, Robinson BW, Lake RA: Synergistic effect of CTLA-4 blockade and cancer chemotherapy in the induction of anti-tumor immunity. PLoS One 2013,8(4):e61895. 10.1371/journal.pone.0061895
29. Rozali EN, Hato SV, Robinson BW, Lake RA, Lesterhuis WJ: Programmed death ligand 2 in cancer-induced immune suppression. Clin Dev Immunol 2012, 2012:656340.
30. The pre-publication history for this paper can be accessed here: http://www.biomedcentral.com/1471-2407/14/969/prepub